

Study: ENGOT-ov49/ NEWTON

A MULTICENTER, OPEN-LABEL PHASE II TRIAL OF A NEW CUSTOMIZED DOSING (RATIONAL ADJUSTMENT OF DOSE TO REDUCE ADVERSE REACTIONS “RADAR” DOSING) OF NIRAPARIB AS MAINTENANCE THERAPY IN PLATINUM SENSITIVE OVARIAN, FALLOPIAN TUBE OR PRIMARY PERITONEAL RECURRENT CANCER PATIENTS

MaNGO Sites

Prov	City	Site	Principal Investigator	Active
MI	Milano	Istituto Europeo di Oncologia	Nicoletta Colombo *	Yes
RE	Reggio Emilia	Arcispedale S. Maria Nuova	Alessandra Bologna	Yes
BS	Brescia	ASST Spedali Civili	Germania Tognon	Yes
PD	Padova	Istituto Oncologico Veneto	Giulia Tasca	Yes
TO	Torino	A.O. Mauriziano	Annamaria Ferrero	Yes
MB	Monza	Fondazione IRCCS San Gerardo dei Tintori	Andrea Alberto Lissoni	Yes
TO	Torino	Ospedale Sant’Anna	Dionyssios Katsaros	Yes
RO	Roma	AOU Policlinico Umberto I	Giorgia Perniola	Yes
MI	Milano	Istituto Nazionale dei Tumori	Francesco Raspagliesi	Yes

***MaNGO Principal Investigator**